Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving viable micro-organism
Reexamination Certificate
2005-05-31
2005-05-31
Gitomer, Ralph (Department: 1651)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving viable micro-organism
C435S030000, C435S032000, C435S261000
Reexamination Certificate
active
06900027
ABSTRACT:
An improved system for screening a multiple of candidate therapeutic or chemotherapeutic agents for efficacy as to a specific patient, in which a tissue sample from the patient is harvested, cultured and separately exposed to a plurality of treatments and/or therapeutic agents for the purpose of objectively identifying the best treatment or agent for the particular patient. The system includes the initial preparation of cohesive multicellular particulates of the tissue sample, rather than enzymatically dissociated cell suspensions or preparations, for initial tissue culture monolayer preparation. Practical monolayers of cells may thus be formed to enable meaningful screening of a plurality of treatments and/or agents. By subjecting uniform samples of cells to a wide variety of active agents (and concentrations thereof), the most promising agent and concentration for treatment of a particular patient can be determined. For assays concerning cancer treatment, a two-stage evaluation is contemplated in which both acute cytotoxic and longer term inhibitory effect of a given anti-cancer agent are investigated.
REFERENCES:
patent: 4423145 (1983-12-01), Stampfer et al.
patent: 4559299 (1985-12-01), Rotman
patent: 4668618 (1987-05-01), Thornthwaite
patent: 4816395 (1989-03-01), Hancock et al.
patent: 4937187 (1990-06-01), Rotman
patent: 4996145 (1991-02-01), Weisenthal
patent: 5242806 (1993-09-01), Yen-Maguire et al.
patent: 5270172 (1993-12-01), Morgan
patent: 5403574 (1995-04-01), Piwnica-Worms
patent: 5443950 (1995-08-01), Naughton et al.
patent: 5607918 (1997-03-01), Eriksson et al.
patent: 5705270 (1998-01-01), Soon-Shiong et al.
patent: 5728541 (1998-03-01), Kornblith
patent: 5789158 (1998-08-01), Knowles et al.
patent: 5874218 (1999-02-01), Drolet et al.
patent: 5888765 (1999-03-01), Patterson et al.
patent: 5942385 (1999-08-01), Hirth
patent: 5972639 (1999-10-01), Parandoosh
patent: 6008007 (1999-12-01), Fruehauf et al.
patent: 6020473 (2000-02-01), Keyt et al.
patent: 6111092 (2000-08-01), Williamson
patent: 6261795 (2001-07-01), Fruehauf et al.
patent: 6303324 (2001-10-01), Fruehauf et al.
patent: 6335170 (2002-01-01), Orntoft
patent: 6416967 (2002-07-01), Kornblith
patent: 6511806 (2003-01-01), Fruehauf et al.
patent: 6664062 (2003-12-01), Stanton
patent: 2002/0168679 (2002-11-01), Naus et al.
patent: 2002/0192638 (2002-12-01), Kornblith
patent: 2003/0096290 (2003-05-01), Fruehauf et al.
patent: 2004/0023375 (2004-02-01), Kornblith et al.
patent: 2004/0072722 (2004-04-01), Kornblith et al.
patent: 2004/0086888 (2004-05-01), Kornblith et al.
patent: WO 96/10742 (1996-04-01), None
patent: WO98/02038 (1998-01-01), None
patent: WO02/33117 (2002-04-01), None
patent: WO2004/015065 (2004-02-01), None
patent: WO2004035833 (2004-04-01), None
“Evaluation of Chemopreventive Agents in Different Mechanistic Classes Using a Rat Tracheal Epithelial Cell Culture Transformation Assay.” Arnold et al., Cancer Research. vol. 55. pp. 537-543 (1995).
“Evidence of a Direct Relationship Between the Increase in the In Vitro Passage Number of Human Non-Small-Cell-Lung Cancer Primocultures and Their Chemosensitivity.” Kruczynski et al., Anticancer Research. vol. 13, pp. 507-514 (1993).
Alley, M., “Morphometric and Colorimetric Analyses of Human Tumor Cell Line Growth and Drug Sensitivity in Soft Agar Culture,” Cancer Research, vol. 51, pp. 1247-1256 (1991).
Andreotti, P., “TCA-100 Tumour Chemosensitivity Assay: Differences in Sensitivity between Cultured Tumour Cell Lines and Clinical Studies,” J Biolumin Chemilumin, vol. 9, pp. 373-378 (1994).
Broadley, C., et al., “A Tissue-Culture Model for the Study of Canine Vocal Fold Fibroblasts,” Laryngoscope, vol. 105, No. 1, pp. 23-27 (1995).
Burczynski, M., et al., “Toxicogenomics-Based Discrimination of Toxic Mechanism in HepG2 Human Hepatoma Cells,” Toxicological Sciences, vol. 58, No. 2, pp. 399-415 (2000).
Cilley, R., et al., “Fetal Lung Development: Airway Pressure Enhances the Expression of Developmental Genes,” Journal of Pediatric Surgery, vol. 35, No. 1, pp. 113-119 (2000).
Dietel, M., et al., “In Vitro Prediction of Cytostatic Drug Resistance in Primary Cell Cultures of Solid Malignant Tumours,” Eur j Cancer, vol. 29A, No. 3, pp. 416-420 (1993).
Dudley, D., et al., “A Human Endometrial Explant System: Validation and Potential Applications,” Am J Obstet Gynecol, vol. 167, No. 6, pp. 1774-1780 (1992).
Frykholm, G., et al., “Heterogeneity in Antigenic Expression and Radiosensitivity in Human Colon Carcinoma Cell Lines,” In Vitro Cell Dev. Biol., vol. 27A, pp. 900-906 (1991).
Fulda, S., et al., “Antiproliferative Potential of Cytostatic Drugs on Neuroblastoma Cells In Vitro,” Eur J of Cancer, vol. 31A, No. 4, pp. 616-621 (1995).
Gamboa, G., et al., “Characterization and Development of UCI 107, a Primary Human Ovarian Carcinoma Cell Line,” Gynecologic Oncology, vol. 58, pp. 336-343 (1995).
Ghosh, A., et al., “Immunohistological Staining of Reactive Mesothelium Mesothelioma, and Lung Carcinoma with a Panel of Monoclonal Antibodies,” J Clin Pathol, vol. 40, pp 19-25 (1987).
Goldsworthy, T., et al., “Concepts, Labeling Procedures, and Design of Cell Proliferation Studies Relating to Carcinogenesis,” Environmental Health Perspectives, vol. 101, supp. 5, pp. 59-66 (1993).
Gress, T., et al., “Development of a Database on Transcribed Sequences in Tumour Cells and Identification of Changes in Transcription Patterns Related to Transformation and Other Tumour Cell Properties for the Global Finger Printing Analysis of Human Pancreatic Carcinoma cDNA Libraries,” Biomed l. Health Res., vol. 24, pp. 171-181 (1998).
Hoffman, R., “The Three-Dimensional Question: Can Clinically Relevant Tumor Drug Resistance be Measured In Vitro?” Cancer and Metastasis Reviews, vol. 13, No. 2, pp. 169-173 (1994).
Kaaijk, P., et al., “Daunorubicin and Doxorubicin but not BCNU have Deleterious Effects on Organotypic Multicellular Spheroids of Gliomas,” British Journal of Cancer, vol. 74, No. 2, pp. 187-193 (1996).
Kitamura, M., et al., “Chemosensitivty of Gastric Cancer Using Adhesive Tumor Cell Culture System,” Oncology Reports, vol. 2, No. 1, pp. 27-31 (1995).
Kornblith, P., “Role of Tissue Culture in Prediction of Malignancy,” Clinical Neurosurgery, vol. 25, pp. 346-376 (1978).*
Kornblith, P., et al., “Variations in Response of Human Brain Tumors to BCNU In Vitro,” Journal of Neurosurgery, vol. 48, No. 4, pp. 580-586 (1978).*
Nance, K., et al., “Immunocytochemical Panel for the Identification of Malignant Cells in Serous Effusions,” Am J Clin Pathol, vol. 95, pp. 867-874 (1991).*
Persons, D., et al., “Interphase Molecular Cytogenetic Analysis of Epithelial Ovarian Carcinomas,” American Journal of Pathology, vol. 142, No. 3, pp. 733-741 (1993).*
Pinkus, G., et al., “Optimal Immunoreactivity of Keratin Proteins in Formalin-Fixed, Paraffin-Embedded Tissue Requires Preliminary Trypsinization,” Journal of Histochemistry and Cytochemistry, vol. 33, No. 5, pp. 465-473 (1985).*
Raju, G., “The Histological and Immunohistochemical Evidence of Squamous Metaplasia from the Myoepithelial Cells in the Breast,” Histopathology, vol. 17, No. 3, pp. 272-275 (1990).*
Singh, H., et al., “Significance of Epithelial Membrane Antigen in the Work-Up of Problematic Serous Effusions,” Diagnostic Cytopathology, vol. 13, No. 1, pp. 3-7 (1995).*
Stephens, S., et al., “A Longitudinal Study of γ-Interferon Production by Peripheral Blood Mononuclear Cells from Breast- and Bottle-Fed Infants,” Clin. Exp. Immunol., vol. 65, pp. 396-400 (1986).*
Stewart, R., et al., “Glutamate Accumulation By Human Gliomas and Meningiomas in Tissue Culture,” Brain Research, vol. 118, No. 3, pp. 441-452 (1976).*
Stoop, J., et al., “Identification of Ma
Gitomer Ralph
Morgan & Lewis & Bockius, LLP
Precision Therapeutics, Inc.
LandOfFree
Method for preparing cell cultures from biological specimens... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for preparing cell cultures from biological specimens..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for preparing cell cultures from biological specimens... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3374509